Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases
COVID-19 trials have relied on symptomatic subjects for judging the effectiveness of vaccine candidates, whereas asy–mptomatic subjects have been suspected as the main driver of the pandemic. An assumption of the same impact on symptomatic and asymptomatic breakthrough infections is shown to be flaw...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1994800 |